AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 407.74B, AbbVie(ABBV) trades at $230.60. The stock has a price-to-earnings ratio of 99.22 and currently yields dividends of 2.8%.
During the trading session on 2026-03-03, AbbVie(ABBV) shares reached a daily high of $235.05 and a low of $230.30. At a current price of $230.60, the stock is +0.1% higher than the low and still -1.9% under the high.
Trading volume for AbbVie(ABBV) stock has reached 772.58K, versus its average volume of 6.16M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
AbbVie Inc. (NYSE:ABBV) on Monday revealed topline results from the Phase 3 AFFIRM study evaluating the efficacy of risankizumab in treating Crohn’s disease. Th...
AbbVie’s (ABBV) treatment of neuroendocrine carcinoma was granted FDA orphan designation, according to a post on the agency’s website. Published first on TheFl...
(RTTNews) - AbbVie (ABBV) on Monday announced positive results from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab in moderately to severely acti...
Analyst ratings
64%
of 33 ratingsMore ABBV News
AbbVie (ABBV) announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety...
AbbVie (ABBV) just combined a fresh FDA approval in blood cancer with a US$380 million manufacturing build out in Illinois, giving investors new information on...
New insider activity at AbbVie ( (ABBV) ) has taken place on February 27, 2026. AbbVie’s Executive Vice President, General Counsel & Secretary, Perry C. Siatis...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has updated a Phase 4 lactation study titled “A Phase 4, Open-Label, Milk-Only...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie Glaucoma Study Tests New Approach to XEN45 Gel Stent. The study, officially titled “...
If you are wondering whether AbbVie’s current share price lines up with its underlying worth, you are not alone. This article is built to help you unpack that q...
The latest announcement is out from AbbVie ( (ABBV) ). On February 24, 2026, AbbVie entered into an underwriting agreement with a syndicate of major banks to i...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.